Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

101.20EUR
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
€101.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
100,499
52-wk High
€129.85
52-wk Low
€66.39

Latest Key Developments (Source: Significant Developments)

Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
Wednesday, 29 Nov 2017 01:01am EST 

Nov 29 (Reuters) - IPSEN SA ::‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​.‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​.‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​.‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​.  Full Article

Ipsen ‍reports Q3 2017 group sales growth of 22.6%​
Thursday, 26 Oct 2017 01:01am EDT 

Oct 26 (Reuters) - IPSEN SA ::‍Q3 2017 GROUP SALES GROWTH OF 22.6%​.‍FULL YEAR 2017 GUIDANCE CONFIRMED.Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 06:58am EDT 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

FDA approves new indication for Ipsen's somatuline depot injection
Monday, 18 Sep 2017 08:00am EDT 

Sept 18 (Reuters) - Ipsen Sa :U.S. FDA approves new indication for Ipsen's somatuline® depot (lanreotide) injection for the treatment of carcinoid syndrome.  Full Article

Ipsen delivers H1 sales growth of 18.8%, upgrades its FY 2017 guidance
Thursday, 27 Jul 2017 01:01am EDT 

July 27 (Reuters) - IPSEN SA : :IPSEN DELIVERS STRONG SALES GROWTH OF 18.8% IN THE FIRST HALF OF 2017 AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2017.H1 GROUP SALES REACHED €919.5 MILLION, UP 18.8% YEAR-ON-YEAR.FOLLOWING STRONG PERFORMANCE IN FIRST HALF OF 2017, GROUP UPDATES ITS FINANCIAL TARGETS FOR FULL YEAR 2017.H1 CORE OPERATING INCOME EUR 240.5 MILLION VERSUS EUR 191.3 MILLION YEAR AGO.FULL YEAR 2017 GUIDANCE OF SPECIALTY CARE SALES GROWTH GREATER THAN 24.0PCT.FULL YEAR 2017 GUIDANCE SLIGHT GROWTH OF CONSUMER HEALTHCARE SALES, AND CORE OPERATING INCOME MARGIN GREATER THAN 25.0% OF SALES.  Full Article

Ipsen receives positive CHMP opinion for approval of Xermelo‍​
Friday, 21 Jul 2017 02:27am EDT 

July 21 (Reuters) - IPSEN SA ::RECEIVES POSITIVE CHMP OPINION FOR APPROVAL OF XERMELO‍​.POSITIVE OPINION BASED ON RESULTS OF TWO RANDOMIZED PHASE 3 TRIALS, TELESTAR AND TELECAST.APPROVAL FOR TREATMENT OF CARCINOID SYNDROME DIARRHEA IN PATIENTS INADEQUATELY CONTROLLED BY SOMATOSTATIN ANALOGUE THERAPY‍​.  Full Article

Exelixis, Bristol-Myers Squibb initiate phase 3 trial
Monday, 10 Jul 2017 08:00am EDT 

July 10 (Reuters) - Bristol-myers Squibb Co ::Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.Bristol-Myers Squibb Co - ‍exelixis, Bristol-Myers Squibb and Ipsen to co-fund trial​.Bristol-Myers Squibb Co - ‍checkmate 9ER is an open-label, randomized, multi-national phase 3 trial that aims to enroll approximately 1,014 patients​.  Full Article

Ipsen announces Dysport co-promotion agreement with Saol
Friday, 30 Jun 2017 08:00am EDT 

June 30 (Reuters) - Ipsen Sa :Ipsen announces Dysport co-promotion agreement with Saol Therapeutics to expand commercial reach in the united states.Entered into an exclusive, three-year agreement with Saol Therapeutics to promote dysport in United States.Additional details of agreement are not disclosed.  Full Article

Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib
Monday, 19 Jun 2017 01:26pm EDT 

June 19 (Reuters) - IPSEN SA ::IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.E.U. REGULATORY SUBMISSION REMAINS ON TRACK FOR Q3 2017.IRC CONFIRMS CABOZANTINIB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO SUNITINIB.  Full Article

Ipsen announces FDA approval of Dysport(Abobotulinumtoxina) for treatment of lower limb spasticity in adults
Friday, 16 Jun 2017 12:00pm EDT 

June 16 (Reuters) - IPSEN SA ::IPSEN ANNOUNCES FDA APPROVAL OF DYSPORT (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS.  Full Article

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​